filmov
tv
KRAS Mutation Subtypes in Advanced NSCLC
Показать описание
Considerations for molecular subtypes of KRAS-mutant advanced non–small cell lung cancer, particularly KRAS G12C.
0:05:57
KRAS Mutation Subtypes in Advanced NSCLC
0:49:07
Unlock KRAS G12C for lung cancer treatment decisions
0:01:10
Kyung Chu on Treating Different Subtypes of the KRAS Mutation
0:04:42
KRAS-Mutant NSCLC: Current Systemic Treatment Options
0:03:57
Future Directions in Managing KRAS-Mutant Advanced NSCLC
0:04:41
History of KRAS Testing in Advanced NSCLC
0:04:09
KRAS G12C Inhibition in Advanced NSCLC: AMG 510
0:07:39
Chemotherapy and Immunotherapy for Patients with KRAS Mutations - ASCO Lung Review 2022
0:04:10
An Overview of KRAS Tumor Biology
0:01:27
Advances in the development of KRAS inhibitors
0:05:23
KRAS G12C Inhibitors: Acquired Resistance and Combo Strategies
0:01:10
Targeting non-G12C KRAS mutations in NSCLC
0:21:36
Strategies for Overcoming KRAS Mutations
0:01:48
Assessing immunotherapy in various subtypes of lung cancer
0:02:52
KRAS-mutant NSCLC: CodeBreak 100 trial of sotorasib
0:02:12
Advances in the management of KRAS-mutant NSCLC
0:05:29
Development of KRAS G12C-Targeted Therapy in NSCLC
0:03:41
Impact of Coalterations on KRAS-Mutant NSCLC
0:04:01
What are the latest developments in KRAS-mutant NSCLC?
0:02:39
Onvansertib for second-line treatment of KRAS-mutated mCRC
0:10:45
What the New KRAS Inhibitor Means for Lung Cancer - Medpage Today
0:02:59
Sotorasib outperforms docetaxel in previously treated KRAS-mutated NSCLC | Melissa Johnson
0:04:44
Practical Considerations for AMG 510 in KRAS-Mutant NSCLC
0:01:37
Treatment strategies for KRAS-mutant NSCLC with co-mutations
Комментарии